Understanding the risk and benefit profile of tamoxifen therapy is increasingly critical because adjuvant tamoxifen is being replaced by aromatase inhibitors in postmenopausal breast cancer patients 16 18 and susceptibility to cardiovascular end points may be one consideration in choosing between the therapies 19 stromectol 12mg online 58 of the dose is excreted in urine as unchanged levomilnacipran